Salivary Gland Cancer

PD-1, PD-L1, CTLA-4, and HER2 positivity are associated with unfavorable clinical outcomes in SDC. Immune checkpoint regulator expression was comparable among AR/HER2 subtypes. PD-1, PD-L1, and CTLA-4 are potential therapeutic targets for SDC, particularly for the HER2/AR double-negative subtype.

The patient remains asymptomatic and is currently monitored without therapy. This case illustrates the occurrence of CLL-type MBL within the lymphoid stroma of a Warthin's tumor, emphasizing the importance of careful histologic and immunophenotypic evaluation and the need for clearly defined diagnostic criteria for extranodal tissue-based MBL.

Features suggestive of MEC include complex branched glandular structures and subtle cytologic atypia. We emphasize the importance of incorporating MAML2 molecular testing into diagnostic algorithms for accurate classification, particularly in challenging lesions with lymphoid-rich stroma.

P1/2, N=242, Recruiting, VM Oncology, LLC | Phase classification: P1 --> P1/2 | N=82 --> 242 | Trial completion date: Jun 2027 --> Jun 2028 | Trial primary completion date: Dec 2026 --> Dec 2027

This neoplasm showed typical morphology with nests of tumor cells with cribriform and papillary architecture and a classic immunohistochemical profile with tumor cells positive for S100 and p63 while negative for p40. Molecular studies showed a NAP1L1::PRKD1 fusion, which has not been previously detected in cribriform adenocarcinoma.

These findings demonstrate that BBI608 effectively inhibits MEC cell proliferation in vitro by inducing Mcl-1-dependent apoptosis. This suggests BBI608 warrants further investigation as a potential therapeutic agent for MEC.

Moreover, MAML2-fused cases might be confused with variant or high-grade mucoepidermoid carcinomas, as they share squamous phenotype and MAML2 rearrangements. The biology of bland cases and their nosology (benign vs low-grade malignant) remain to be further characterized.

CSG is a rare benign tumor that predominantly affects the parotid gland in female patients, typically presenting as a multicystic lesion. Surgical excision remains the treatment of choice, with a generally favorable prognosis.

Detailed, systematic histopathological and immunohistochemical (IHC) assessment for validation and confirmatory diagnosis is imperative. An added evaluation for tumour outcome with affirmative markers (DOG1), proliferative markers (Ki67), add value in diagnosis and prognostication of this tumour.

Surgical resection is the main treatment, and diagnosis requires confirmation through histopathology, immunohistochemistry, and special staining. CRTC1-MAML2 fusion can also assist in diagnosis.

BCA is a very rare tumor of the lacrimal gland, but complete resection is the effective treatment. Postoperative follow-up is necessary due to the possibility of malignant transformation.

Recognition of LG-TNBCs is essential to prevent overtreatment and guide personalized patient management. Molecular characterization provides diagnostic confirmation and therapeutic opportunities, particularly for NTRK-fusion-positive tumors treatable with targeted inhibitors, highlighting the importance of precision medicine in rare breast tumors.